Overview of measures applied to designated persons according to the FAQ.

The Ministry of Industry and Trade partially legalized parallel import in Russia by approving the Decree No. 1532 of 19 April 2022 “On goods admissible for parallel import, that shall not be restricted by art. 1359(6) and 1487 of the Civil Code” . The list includes well-known brands of cars, home equipment, smartphones, etc.

Ministry of Industry and Trade develops an order with a list of goods and brands that can be imported without the permission of the copyright holder.

On 8 March 2022, Federal Law No. 46 “On Amending Certain Legislative Acts of the Russian Federation” entered into full force and effect, suggesting considerable changes in regulations and intellectual property in the pharmaceutical sphere.

Since 1 March 2021, the Pharmaceutical Register of the Eurasian Patent Office (EAPO) is available on the official website of the Eurasian Patent Office. The Register contains information on Eurasian patents protecting active substances of drugs.

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”¹.

On March 3, 2020, the Russian Government introduced to the State Duma the Draft Law on amendments to the Russian Civil Code, namely, article 1360.1.

Under the Federal Law “On drugs circulation” (Law), information on state registration of drugs in Russia shall be publicly available.

As outlined in art. 1247 of the Russian Civil Code, any applicant may choose one of the options how to be represented before Rospatent.

On 4 July 2018, Russian IP Court rendered a landmark judgment in case No. A40-132026/2017.